Q2 FY24 Financial Highlights

Lupin Today Operating from a position of strength Global Presence 13th Local Leadership LUPIN Geographically Diverse (FY23 Sales) Company (by sales¹) Largest Generic 3rd Largest in the US 7th India Pharma (by prescriptions³) Market Rank (by sales³) 37% INDIA 8% Developed Markets Largest South Africa Gx (by sales5) 32% US 14% Emerging Markets 7% Developing Adjacencies ΑΡΙ $2 bn Annual sales in FY23 $233 mn EBITDA in FY23 20,500+ Lupinytts Reaching lives in 100+ countries 1 Global ranking based on LTM June-23 sale Largest 4th Australia 7th Gx (by sales) With Global Infrastructure And Growing Sustainably ~13% reduction in Scope 1 and 2 emissions² 13 IQVIA Qtr Sep-23 14 IQVIA MAT Mar-23 Adding 22MW Renewable energy capacity in FY24 15 IQVIA MAT Sep-23 15 Manufacturing R&D 7 Sites Sites Renewable energy share of 5% in FY23 across India, the US, Netherlands, Brazil and Mexico | 2 Reduction in FY23 from base of FY20 15

View entire presentation